Switch to:
Also traded in: Australia, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
AVMXY's Cash-to-Debt is ranked higher than
94% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. AVMXY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AVMXY' s Cash-to-Debt Range Over the Past 10 Years
Min: 16.69  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
AVMXY's Equity-to-Asset is ranked higher than
97% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. AVMXY: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
AVMXY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.91 Max: 0.99
Current: 0.92
0.51
0.99
Interest Coverage No Debt
AVMXY's Interest Coverage is ranked higher than
94% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. AVMXY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AVMXY' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -2.66
WACC vs ROIC
3.35%
-700.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1420.82
AVMXY's Operating Margin % is ranked lower than
95% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. AVMXY: -1420.82 )
Ranked among companies with meaningful Operating Margin % only.
AVMXY' s Operating Margin % Range Over the Past 10 Years
Min: -1723.37  Med: -288.3 Max: -178.34
Current: -1420.82
-1723.37
-178.34
Net Margin % -779.39
AVMXY's Net Margin % is ranked lower than
92% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. AVMXY: -779.39 )
Ranked among companies with meaningful Net Margin % only.
AVMXY' s Net Margin % Range Over the Past 10 Years
Min: -1614.68  Med: -242.44 Max: -57.58
Current: -779.39
-1614.68
-57.58
ROE % -84.29
AVMXY's ROE % is ranked lower than
85% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. AVMXY: -84.29 )
Ranked among companies with meaningful ROE % only.
AVMXY' s ROE % Range Over the Past 10 Years
Min: -145.87  Med: -87.94 Max: -17.34
Current: -84.29
-145.87
-17.34
ROA % -71.80
AVMXY's ROA % is ranked lower than
84% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. AVMXY: -71.80 )
Ranked among companies with meaningful ROA % only.
AVMXY' s ROA % Range Over the Past 10 Years
Min: -111.43  Med: -65.83 Max: -13.45
Current: -71.8
-111.43
-13.45
ROC (Joel Greenblatt) % -592.08
AVMXY's ROC (Joel Greenblatt) % is ranked lower than
81% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. AVMXY: -592.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVMXY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4361.27  Med: -834.71 Max: -248.87
Current: -592.08
-4361.27
-248.87
3-Year Revenue Growth Rate -39.40
AVMXY's 3-Year Revenue Growth Rate is ranked lower than
91% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. AVMXY: -39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVMXY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -39.4 Max: 8.7
Current: -39.4
0
8.7
3-Year EBITDA Growth Rate -5.20
AVMXY's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. AVMXY: -5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AVMXY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.1  Med: -11.3 Max: 30.8
Current: -5.2
-64.1
30.8
3-Year EPS without NRI Growth Rate -8.00
AVMXY's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. AVMXY: -8.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AVMXY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.9  Med: -16 Max: 11.9
Current: -8
-57.9
11.9
GuruFocus has detected 5 Warning Signs with Avita Medical Ltd $AVMXY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVMXY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with AVMXY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices  
Compare:OTCPK:IVOB, OTCPK:TLTFF, OTCPK:BLOZF, OTCPK:BTCY, NAS:TNDM, AMEX:ELMD, OTCPK:BSGM, NAS:MGCD, OTCPK:VICA, OTCPK:GIDYL, OTCPK:DIZTF, NAS:SRTS, OTCPK:LCTC, NAS:KOOL, OTCPK:FGCN, NAS:ETRM, NAS:SPAN, OTCPK:CRVW, OTCPK:TITXF, OTCPK:QTVLF » details
Traded in other countries:AVH.Australia, GCR.Germany,
Headquarter Location:UK
Avita Medical Ltd develops and distributes autologous regenerative products. The Company's product portfolio includes ReCell for burns procedures, ReGenerCell for chronic wounds and ReNovaCell of restoration of pigmentation and cosmesis.

Avita Medical Ltd. manufactures & sells regenerative & respiratory medical devices. It offers tissue-engineered products for wound & skin defects, spacers for adolescent & adults, ReCell Spray-On-Skin, Funhaler for asthma & Breath-ATech, among others.

Top Ranked Articles about Avita Medical Ltd

Avita Medical Appoints a Leading Health Economics Group

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 28, 2016) - Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY) has engaged a leading Health Economics Group to evaluate how its novel regenerative medical device, ReCell®, can save money at US burns centres, the Company said today. The regenerative medicine company, which specializes in new treatments for wounds and skin defects, said the commissioned study would be funded by BARDA, the US federal authority which prepares the US for possible mass casualty events, and with which Avita has a US$61.9m (A$84.2m) development and procurement contract. IMS Health, one of the world's leading health economic groups, had been selected for the project, which should take six to eight months, and has a broad remit to explore the potential cost savings from all major interventions for burns treatment, including wound bed preparation, grafting and scar management. In its proposal to Avita, IMS reported that burns place an economic burden on the US medical system of more than $1.5bn pa, half of this spent on the some 40,000 patients who are hospitalised with severe burns. The agency said that these costs could increases significantly if there was armed conflict or a mass casualty event, given that up to 10% of combat injuries are burns, and that burns typically increase three-fold amongst civilians during wartime. "Burns remain the fourth most common trauma in the international community, and cause 1% of non-fatal injuries in the US" IMS reported. "Although burn fatalities have fallen over time, effectively managing burns remains a challenge, with significant morbidity and mortality among burn patients. Potential effects include shock, infection, electrolyte imbalance, respiratory distress, incapacitation, disfigurement, pain, and psychological complications due to scarring and deformity." In a review of potential economic benefits, IMS summarised that ReCell®'s technology achieved faster epithelialisation of widely-meshed skin graft interstices and thus minimized donor site requirements. It also showed improved long-term functional and aesthetic outcomes of grafting while also minimizing follow-on procedure requirements, the IMS report said. "We have data to show that ReCell® is safe, and very effective in treating burns," said Avita CEO Adam Kelliher. "What we must also demonstrate is how our approach, in conjunction with other treatments, can save public health bodies money, by getting patients out of hospital faster, and improving their outcomes. The IMS study will generate standard budget impact metrics vital to driving discussions on reimbursement and access." ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


USA

The Ruth Group

David Burke, Investor Relations

Kirsten Thomas, Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected]

/ [email protected]


Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Regenerative Medicine Publishes Key Findings From Avita Medical's 2016 Skin Regeneration Symposium

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 27, 2016) - Avita Medical's autologous skin healing technology shows strong effectiveness in treating burns, chronic wounds and aesthetics, and will help strained public health budgets, according to a comprehensive review of data presented at a scientific symposium by a leading Regenerative Medicine journal, the Company said today. Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, ran the 4th Skin Regeneration Symposium (SRS) in Cambridge, UK in April 2016. Data from the event, presented by leading clinicians worldwide to the some 140 attendees, has now been published on RegMedNet.com, which is the online platform for peer-reviewed journal Regenerative Medicine. The full three-part review together with clinician interviews are published with free access at Regenerative Medicine.

Part 1 covers the REPAIR session of the Symposium, focused on ReCell®, Avita's proprietary technology for the treatment of burns
Part 2, on the RESTART session which concentrated on ReGenerCell™, Avita's chronic wounds device that is used to treat long standing wounds such as Venous Leg Ulcers and Diabetic Foot Ulcers
Part 3 concludes with the RESTORE session which looked at the use of ReNovaCell™, Avita's device which covers aesthetic applications including vitiligo and scarring

During the Symposium, Regenerative Medicine interviewed leading clinicians about their experience pioneering Avita Medical's autologous skin healing technology based on its RES™ -- Regenerative Epithelial Suspension -- technology that uses just a small sample of the patient's skin. The experts had all presented strong clinical results in their various areas of expertise, and agreed that a call for action is now needed to move Avita's medical devices into mainstream medical practice, to improve lives of patients, whilst saving healthcare costs.
"This versatile technology could be used in a number of ways in the same patient without an incremental increase in cost, since length of stay can be reduced so dramatically," said Dr James H. Holmes IV, Wake Forest University School of Medicine. "That can have a huge impact on the healthcare system and society as a whole, since the patient is able to return to a functional state more quickly: whether that's going back to work, or driving a car." His views were shared by Mr Paul Hayes, Vascular Surgeon at Addenbrooke's Hospital, who explained that VLUs consume 10-20% of vascular surgery clinic time, while great resources were also being spent on treating Britain's some 100,000 DFU patients1. Mr Hayes said it was much cheaper to treat patients as an out-patient, which was one of the attractions to ReGenerCell™. "If acute wounds are referred into secondary care earlier, we could actually stop them from being so difficult to treat," Mr Hayes commented. "With the exception of diabetic foot ulcers, chronic wounds have not become headline-grabbing conditions. So we need to have a group of interested individuals who can be dedicated to the cause." Dr Nik Georgopoulos, Senior Lecturer, Department of Biological Sciences at the University of Huddersfield, supported Mr Hayes call for action, saying, "By supporting the way the device operates with biological evidence we are able to give more confidence to the clinicians who use it on its efficacy. The economic burden of chronic wounds is not in the range of the millions (of pounds), it's in the range of billions." Adam Kelliher, CEO of Avita Medical, concluded: "Regenerative medicine and using the body's own healing responses is becoming more widespread in medical practice. The body of data supporting the efficacy of our devices is growing every day. Whilst mainstream adoption of new technologies rightly takes time, the clinicians pioneering our technology agree that barriers to widespread uptake need to be overcome. The use of Avita's technology positively impacts patients with quicker and more significant wound healing, less inconvenience and much less pain." Indicators have shown Avita's technology also saves money for healthcare services when replacing or combined with traditional methods, the Company says. It will be gathering important pharmaco-economic data during its ongoing clinical studies, to support adoption of its products. With data collected from over 6,000 procedures worldwide, Avita's patented technology is CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. 1 https://www.diabetes.org.uk/FactsandStats ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


USA

The Ruth Group

David Burke

Investor Relations

Kirsten Thomas

Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected] / [email protected]


Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Avita Medical Awarded US$7.96m in BARDA Extension Deal

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 26, 2016) - Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY)

Additional non-dilutive funds to accelerate US market approval and product launch
Support aims to increase familiarity/acceptance in US Burn Centers, demonstrate economic benefits and increase acceptance of ReCell® in US Burn Centers
Funds will be deployed to support recruitment of additional US operational staff

A US Federal authority charged with supporting development of medical countermeasures for possible mass casualty events has agreed to fund Avita Medical a further $US7.96 million to support the regenerative medicine company in its plans for US market approval and product launch of ReCell®, the Company said today. Avita Medical Limited, (ASX: AVH) (OTCQX: AVMXY) which makes Autologous Cell Harvesting Devices for treatment of burns, chronic wounds and certain aesthetic conditions, said the award supplements the contract executed last September with the Biomedical Advanced Research and Development Authority (BARDA), worth up to $US53.9m. The initial contract with BARDA, an authority under the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services, includes procurement and various elements of support for late-stage development of ReCell®. The new contract addendum, worth up to $US7.96 million (AUD $11m), commences immediately, giving further operational support to facilitate the overarching objective of BARDA for preparedness via securing effective treatment of burn injuries secondary to detonation of a nuclear device. The additional funds will bolster ongoing work toward the Company's filing of a PMA application, along with funding new initiatives toward gaining familiarity and acceptance of ReCell® within US Burn Centers, including health economic modelling of the benefits associated with ReCell® for burns treatment and continuing engagement with US Burn Centers for use of ReCell® under the Company's open Investigational Device Exemptions (IDEs) for treatment of a range of burn injuries including the particularly extensive burns associated with Compassionate Use. Towards this, Avita will utilize these funds towards recruitment of new personnel at the Company's office in Northridge, California. The new staff will be focused on such operational areas as regulatory, supply chain, quality systems, clinical support and reimbursement. "This welcome infusion of significant non-dilutive capital to fund our activities in the US, which we would otherwise have had to fund ourselves, greatly supports Avita Medical on its commercial journey," said Avita CEO Adam Kelliher. "We are particularly excited about the health economics support, which we hope will enable us to show how innovative approaches such as ours can both help burn victims and save money as these are the key drivers to support our reimbursement efforts." BARDA's initial contract funds the completion of Avita's FDA approval trial, for which all treatments have now been completed, and the cohort is currently being observed over a 52-week safety period. As well as an initial procurement of some 5,000 devices, the contract also funds an education programme, so that burns surgeons across the US will be trained as well as supplied with the medical devices, should there be a mass casualty event involving numerous burn injuries. The procurement order could be placed prior to FDA approval based on the possibility for deployment of ReCell® devices under an Emergency Use Authorisation. The Company said it is in close communication with BARDA on the progress of its FDA approval pathway, which is scheduled to complete in calendar Q3 2017.  ABOUT RECELL® AND RES™

ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin, yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin. ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


USA

The Ruth Group

David Burke

Investor Relations

Kirsten Thomas

Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected] / [email protected]


Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Avita Medical to Present at Global Chinese Financial Forum

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 22, 2016) - Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, today announced that it will present on its commercial strategy in China at the Global Chinese Financial Forum 23 June 2016 in Shanghai. More than 100 investors from publicly listed companies, private industrial companies, private equity firms, high net worth individuals, and provincial state-owned enterprises are to attend the event at Shanghai's Shangri-La Hotel in Pudong. Avita Medical CEO Adam Kelliher is scheduled to deliver a 25-minute presentation, titled "Bringing Innovative Regenerative Medicine to China through Distribution Relationships." The annual forum has been running since 2007, and one of its main aims is to connect innovative companies with China's investment community. "With an aging population, economic growth, a rising middle class, and government support, the country's annual healthcare expenditure is projected to reach US$892 billion by 2018," the organisers explained. "China's government has identified healthcare reform to be an important field, and have introduced policies to encourage private and foreign investments into the healthcare sector. This growth has led to significant opportunities for global life science companies that are focused on developing new pharmaceuticals, medical devices and other products in terms of capital raising and commercialization." Avita said its attendance was part of its strategic focus on China, where it is CFDA-approved and has had a market presence for five years. The Company in March signed an exclusive distribution deal for China with the country's leading healthcare group, Sinopharm. Avita's sales are focused in several leading hospitals in the main cities of Beijing, Shanghai and Guangzhou, with activities concentrated primarily in the fields of burns, plastics and repigmentation. Avita's devices have been used in leading research, including a randomized trial that showed the approach could regenerate healing in chronic leg ulcers. "China is a country of real interest for us, from both clinical and commercial perspectives, and so the GCFF conference is very timely," said Avita CEO Adam Kelliher. "Finding the right partners will be vital for us to extend our reach into the Chinese market, where we see massive potential for our devices and our unique approach to healing damaged skin." ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION



Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]



USA

The Ruth Group

David Burke

Investor Relations

Kirsten Thomas

Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected]

[email protected]



Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Avita Medical Signs Deal for Distribution in Malaysia

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 7, 2016) - Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY) has furthered its expansion into the Asian market with the appointment of a specialized wound care distributor for its products in Malaysia. The Company said it had concluded a deal with Mintcare, which specialises in the distribution of wound care products throughout the Asia-Pacific region. Avita Medical said Mintcare would first focus on Malaysia in its marketing of Avita's regenerative medical devices for burns, wounds and skin conditions. Mintcare has a 4-person sales force in the South-east Asian country, where vitiligo alone is reported to affect an estimated 450,000 people1, chronic wounds some 180,0002 patients, and large burns annually leave about 1,2003 Malaysians hospitalized. Avita Medical's ReCell® technology works through the rapid delivery of viable cells harvested from a piece of the patient's own skin and is administered by spraying the cells onto the affected area to trigger healing. ReCell® will be launched at an international wound care conference in Sabah, Malaysia in August. Singapore-based Mintcare also has commercial presence in Hong Kong, Indonesia, Philippines, Sri Lanka, Thailand, and Vietnam, and its range includes wound care products that complement Avita's offering. "The addition of ReCell to the Mintcare product portfolio brings great synergistic opportunities," said Mintcare Director Lamine Guendil. "Mintcare has successfully developed a distribution network in South East Asia specifically in the chronic wound care field, primarily targeting diabetic foot ulcers and venous leg ulcers with topical oxygen therapy. We're confident our many years of experience in this industry and our in-depth knowledge of the local environment and culture, will deliver success to ReCell® in Malaysia." Avita Medical's CEO, Adam Kelliher, said the deal in Malaysia was another milestone in the Company's strategy to roll-out its regenerative medical devices in key Asian markets. In recent months, the Company has announced distribution agreements with parties in China, Japan and South Korea, and it has been active in Taiwan, where it donated devices following a mass casualty event last summer in a waterpark that left some 500 people burned. "The deal with Mintcare will give Avita Medical an active presence to deliver our innovative treatments to Malaysia, a market of 30 million people, and further underscores the significance of the broader Asian healthcare market for our company," Kelliher said. "We will keep developing our distributor network in the region so that we are well-placed to address the significant commercial opportunities in Avita." ABOUT RECELL® AND RES™

ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin, yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin. ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com. 1 Su-ming Wong et al, 2009

2 Frost & Sullivan market analysis, 2011

3 Tam Song et al, 2015


FOR FURTHER INFORMATION



Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]



USA

The Ruth Group

David Burke, Investor Relations

Kirsten Thomas, Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected]

/ [email protected]



Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Clinical Study in UK to Evaluate ReGenerCell(TM) for Diabetic Foot Ulcer Treatment

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - May 30, 2016) - Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)

Study will evaluate preliminary safety and effectiveness in a cohort of up to 24 patients
Innovative regenerative technology will use patients' own skin cells to try to close chronic Diabetic Foot Ulcer (DFUs)
DFUs represent a significant new potential patient population for Avita Medical

The first patient suffering from a Diabetic Foot Ulcer (DFU) has been enrolled in a clinical trial in the UK aimed at evaluating the feasibility of the medical device ReGenerCell™ in the safe and effective treatment of this widespread complication of diabetes, Avita Medical said today. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, said the new research takes Avita into a significant new indication area, after the recent release of positive study outcomes for ReGenerCell™ in the treatment Venous Leg Ulcers (VLUs). The DFU clinical study has now started at Manchester Royal Infirmary, with London's King's College and Northwick Park hospitals to join shortly. DFUs are a common and growing complication of diabetes, and can often lead to amputation amongst the UK's 4 million diabetics, whose condition costs the NHS £10bn a year to treat.(1) The Company said the first patient had been treated at the Manchester Royal Infirmary and that the study aimed to enroll up to 24 patients with DFUs, who will each be followed over a 26-week evaluation period. The ReGenerCell™ device enables medical professionals to create an autologous suspension of skin cells, which is then applied to the patient's wound to trigger healing. The treatment will be evaluated as an adjunct to standard care treatments, such as debridement, cleansing, dressings, and offloading. As well as the key outcome measures of incidence of healing and rate of wound closure, the study will also explore patient and physician satisfaction, the Company said. "We are keen to evaluate any treatment that has the potential to improve patient care and at the same time reduce cost," said Mr. Tawqeer Rashid, Chief Investigator and Consultant Vascular Surgeon at Manchester Royal Infirmary. "With this study we will be evaluating the clinical benefits of the ReGenerCell™ treatment for patients whose quality of life is often severely reduced." The Company said it had embarked on the study following many successful patient outcomes, indicating that the regenerative approach could be a very effective means of treating DFUs, which are typically long-term open wounds resistant to most standard treatments. Pioneering work at a wound clinic in Italy achieved complete wound closure for three DFUs of four within 50 days of treatment(2), and similarly successful outcomes have been shown in DFU patients treated in the UK, notably those treated by Dr Harvey Chant at the Royal Cornwall Hospital, the Company said. "Clinicians from different parts of the world have found ReGenerCell™ to be an effective treatment of diabetic foot ulcers in their practices. A clinical study will allow us to formalize our understanding of the treatment effect and will serve in the development of the clinical guidance and evidence needed for commercialization," said Andrew Quick, Avita's Senior Vice President of Clinical Development. The Company said that diabetes was a growing and significant healthcare problem in many of the markets in which it has approval, including Australia (1.7million)(3) and China, which has 114 million diabetics: 1 in 3 in the world.(4) "Most healthcare authorities around the world are facing an epidemic of diabetes and one of their most expensive challenges is how to treat foot ulcers which, sadly, once started, typically lead to a slow and lingering decline," said Avita CEO Adam Kelliher. "If our approach can get these ulcers to heal, then it could offer hope to many diabetics around the world." Using a small sample of skin, the ReGenerCell™ device enables the production of a Regenerative Epithelial Suspension (RES™). The autologous suspension contains the multi-phenotype cells and wound-healing factors essential for natural healthy skin regeneration and healing. The procedure performed at the patient's bedside takes about 30 minutes from collecting the skin sample to treatment of the affected area. In cases of chronic wounds, including DFUs and VLUs, the suspension is sprayed or dripped onto the skin. It has been shown to significantly reduce the healing time of wounds and leaves the patient with skin with similar elasticity, texture and pigmentation to surrounding skin, with limited scarring. ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com. For information on ReGenerCell™, visit: www.avitamedical.com/products/recell-for-chronic-wounds/ 1 https://www.diabetes.org.uk/About_us/News/Number-of-people-with-diabetes-reaches-over-4-million/
2
DeAngelis B, Migner A, Lucarini L, Agovino A, Cervelli V. The use of a non-cultured autologous cell suspension to repair chronic ulcers. International Wound Journal 2013; doi: 10.1111./iwj. 12047 [Epub]

3 https://www.diabetesaustralia.com.au/diabetes-in-australia
4
 Yu Xu, Limin Wang, Jiang He, et al. Prevalence and Control of Diabetes in Chinese Adults. JAMA 2013; 310(9): 948-59


FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone: 61 (0) 8 9474 7738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone: 44 (0)20 7866 7860

[email protected]



USA

The Ruth Group

David Burke, Investor Relations

Kirsten Thomas, Public Relations

Phone: 1 (646) 536-7009

/ 1 (508) 280-6592

[email protected]

/ [email protected]



Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 (0) 3 9620 3333

[email protected]





Read more...
Avita's Novel ReNovaCell(TM) Technology Offers Key Advantages in Skin Repigmentation of Burn Scars, When Combined With Medical Needling

Data Published in Peer-Reviewed Journal Burns

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - May 9, 2016) -  

Combination therapy offers new approach to burn scar revision
Statistically significant, objectively measured scar repigmentation improvement

The combination of medical needling with a suspension of epithelial cells provided by ReNovaCell™ can restore pigment on burn scars, according to a randomised clinical trial from Germany published in Burns, the journal of the International Society for Burn Injuries, Avita Medical said today. Avita Medical Ltd, (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said the research offered a new and practical combination approach for medical professionals in the aesthetic sector aiming to address long-term scarring from burns, which remains a serious physical and psychological problem for affected patients. ReNovaCell™ enables plastic surgeons to quickly create an autologous suspension of cells that can then be applied to a wound bed, supporting healing of the top epithelial skin layer. Crucially, this Regenerative Epithelial System (RES™) includes melanocytes, which govern skin colour. These new findings are supported by other clinical data showing ReNovaCell™ can restore pigmentation. The article in Burns, titled Combination of Medical Needling and non-cultured autologous skin cell transplantation (ReNovaCell) for repigmentation of hypopigmented burn scars,1 describes a study involving the treatment of 20 patients, mean age of 33 years (6-60 years), with scars from deep second- and third-degree burns. Researchers deployed medical needling -- also called percutaneous collagen induction -- to improve scar texture and appearance by inducing microtrauma using a roller covered in 3mm needles. Medical needling has been shown to improve various characteristics of scars, but the technique does not typically address depigmentation issues, particularly over large areas. The researchers hypothesized that the use of ReNovaCell would complement the medical needling technique by introducing pigment-producing cells. Scars selected for treatment were on prominent areas such as the face, neck, chest and arms, with an average treatment surface area of 94 cm2 (15-250 cm2). The study was designed as a within-subject comparison of 3 treatment areas for each participant, with each area randomly assigned to receive (1) no treatment, (2) medical needing and ReNovaCell or (3) medical needling without ReNovaCell. For each participant, one needled scar area was treated with RES™, created on ReNovaCell™ medical devices. Patients were evaluated after 3, 6, 9 and 12 months by an observer blinded to treatment assignment and pigmentation levels were objectively measured using specialized instrumentation. Patients also rated the outcomes of treatment.
The blinded-observer scar ratings, patient scar ratings and objective pigmentation measures all showed statistically significant improvements 12 months after treatment with ReNovaCell. Under the Patient and Observer Scar Assessment Scale, median patient rating of pigmentation was 50% improved, and the median overall scar rating improved 57.1%, while observer ratings respectively showed 37.5% and 38.5% improvements. Taken together, the pigmentation ratings and objective measures indicate individual improvement in 17 of the study's 20 participants, the researchers reported. Melanin increases seen 12 months after ReNovaCell™ treatment were also statistically significant, showing a 29.3% improvement, while control areas showed no increase, they said.
"The combination of medical needling and ReNovaCell™ is a very promising approach to repigmenting large hypopigmented burn scars," said Dr Matthias Aust, Assistant Professor, Malteser Hospital, and co-author of the paper. "These positive results suggest that medical needling is delivering the melanocytes of the cell suspension through the needling channels straight onto the basal membrane."
Plastic surgeons treating burn scars have a number of options. Split-thickness autografts can produce a good pigmentation outcome, but this is an invasive approach, requiring donor skin sites to match the scar area. Cultured skin cell transplantation can also be deployed, but it takes weeks to prepare the cells. Medical needling alone is known to improve skin elasticity, moisture, erythema and transepidermal water loss, but has not been shown to improve repigmentation of large hypopigmented scars. In this context, Avita Medical said deploying needling with ReNovaCell™ offered key advantages: the ability to cover large wounds through a small donor site, is less invasive and crucially, delivers melanocytes to address hypopigmentation. "This new approach, of combining ReNovaCell™ with medical needling, is simple, effective and enables patients to enjoy the synergistic benefits of both procedures," said Adam Kelliher, CEO of Avita Medical. "Ultimately, scar revision is about achieving the most optimal result, and from this perspective, we believe this combination could create a new benchmark for patient outcomes." ABOUT AVITA MEDICAL LIMITED Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's regenerative product portfolio includes ReCell® for burns aimed at plastic reconstructive procedures, ReGenerCell™ for chronic wounds and ReNovaCell™ of restoration of pigmentation and cosmesis. ReCell®, ReGenerCell™ and ReNovaCell™ are patented, CE‐marked for Europe. ReCell® is TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. trial is well underway aimed at securing FDA approval. To learn more, visit www.avitamedical.com. About ReNovaCell™
ReNovaCell™ is a medical device which enables clinicians to safely and rapidly create a treatment solution for pigmentation defects from a patient's own skin.
Using a small sample of skin, the device enables the production of a Regenerative Epithelial Suspension (RES™). The autologous suspension contains the multi-phenotype cells and wound-healing factors essential for natural healthy skin regeneration and healing. The procedure performed at the patient's bedside takes about 30 minutes from collecting the biopsy to spraying of the suspension onto the affected area. ReNovaCell™ can be used in conjunction with conventional treatments for pigmentation defects, including scars, wrinkles and lesions associated with vitiligo and piebaldism, and has been used safely in thousands of treatments worldwide.
For more information, visit: www.avitamedical.com/renovacell 1 Busch KH, Bender R, Walezko N, Aziz H, Altintas MA, Aust MC. Combination of medical needling and non-cultured autologous skin cell transplantation (ReNovaCell) for repigmentation of hypopigmented burn scars. Burns (2016). In press. http://dx.doi.org/10.1016/j.burns.2016.04.009


FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269770

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]



USA

The Ruth Group

David Burke

Investor Relations

Kirsten Thomas

Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected]

/ [email protected]



Australia

Monsoon Communications

Rudi Michelson

Investor Relations / PR

Phone: 61 3 9620 3333

[email protected]





Read more...
Research Confirms That ReCell(R) Reduces Long-Term Scarring and Itching Outcomes in Pediatric Burns Treatment

UK Study Results Presented at American Burn Association (ABA) Annual Meeting

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - May 5, 2016) - Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) -- The ReCell® Autologous Cell Harvesting Device effectively reduces the occurrence of long-term scarring and itching symptoms associated with pediatric burn treatment, compared to various treatment modalities, according to results from a UK study presented at a major burns conference this week. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, reported key findings from the retrospective analysis presented this week at the American Burn Association (ABA) 48th Annual Meeting, being held May 3-6, 2016 in Las Vegas, NV. In one of the first studies to explore long-term outcomes, the Pinderfields Hospital Regional Burns Unit, in Wakefield, United Kingdom, evaluated long-term outcomes in 100 pediatric patients with partial-thickness scalds. The patients, followed for three to four years, were treated with five different treatment modalities: ReCell® with conventional dressings, ReCell® with biological dressings, biological dressings, conventional dressings, and split-thickness skin grafting. Results, presented by Dr Elliott Cochrane (Abstract #167), showed that ReCell® in combination with biological dressings was the most effective modality in terms of scar outcomes. Of the patients receiving split-thickness skin grafts, an 80% incidence of scarring was reported. This was reduced to 50% in patients who were treated with biological dressings alone. The incidence of scarring was just 25% for those receiving ReCell® with conventional dressings, and the lowest incidence, 22%, was observed for those treated with ReCell® combined with biological dressings. Patients complained of a higher level of itchiness (18%) with biological dressings (without ReCell), compared with 11% for ReCell® with biological dressings and 0% for ReCell® with conventional dressings. The researchers concluded that the treatment route combining biological dressings and Regenerative Epithelial Suspension™ (RES™) generated by ReCell® is the optimal wound healing environment and provides reduced patient discomfort as the wound re-epithelializes. "These results confirm previously published work of Wood et al (2012) and what burns surgeons routinely using ReCell already know: that ReCell® can outperform alternative treatment options when considering key, practical clinical risks that patients commonly suffer from when undergoing burn treatment," said Avita CEO Adam Kelliher. "Scarring and itching are constant issues for our patient group, and we should always consider that about half of burns in Europe happen to children, who will have to endure these outcomes for life. Proving long-term benefit is of real significance." ABOUT RECELL® AND RES™ ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin. ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal U.S. trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269770

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]



USA

The Ruth Group

David Burke, Investor Relations

Kirsten Thomas, Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected]

/ [email protected]



Australia

Monsoon Communications

Rudi Michelson

Investor Relations / PR

Phone: 61 3 9620 3333

[email protected]





Read more...
Avita Medical's ReCell Technology Demonstrated at Vitiligo Conferences in China

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - May 2, 2016) - Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY)

More than 300 Chinese clinicians witness live demonstration of ReCell® technology
Borun Group anticipates making ReCell® 'routine' treatment at its 23 hospitals
China is home to an estimated 12 million vitiligo patients

Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY) has further extended its push into lucrative global markets by demonstrating its ReCell® autologous cell harvesting technology at a series of conferences in China investigating treatments for the skin condition vitiligo. Avita Medical, which is a regenerative medicine company specialising in the treatment of burns, wounds and skin defects, said more than 300 Chinese dermatology experts attended the presentations in the cities of Guangzhou, Chengdu and Giuyang aimed at explaining how the Company's ReCell® medical device can treat pigmentation disorders. Dr Fiona Wood, co-inventor of ReCell®, and Dr Albert Wolkerstorfer, from the Netherlands Institute for Pigment Disorders (SNIP) both explained their work, and a ReCell® clinical procedure was broadcast live to delegates to show its ease of use and its straightforward incorporation into routine clinical practice. The groups were also briefed by Dr Zhifei Liu and Dr Ang Zeng of Peking Union Medical College Hospital (PUMCH) and Dr Luo, of Air Force General Hospital, Beijing: Chinese doctors who are all experienced users of the device. The Company said the events were part of its strategy of increasing device usage in China, a target market in its international distribution activities. The conference follows the March announcement that Avita had signed a partnership with China's largest medical and healthcare group, Sinopharm. "This is another important step in delivering our regenerative medicine to where it's needed,": said Avita CEO Adam Kelliher. "China has many vitiligo patients, and we know that particularly for acute cases, our approach can bring real benefit. We need the right partners to reach this patient group, and we believe we have such a partner in the Borun Group." The Borun Group is one of China's leaders in vitiligo treatment, and it runs 23 hospitals and employs 138 clinicians specialising in the treatment of vitiligo. It began employing the ReCell® method in 2014 and now uses it in ten of its hospitals. The Borun Group expects more than 300,000 visits from vitiligo patients in China this year, and said it typically deploys ReCell® for acute cases. "The excellent presentations about how ReCell can be wisely used for large-area vitiligo patients make us more confident to include ReCell surgical treatment as a routine therapy in all vitiligo hospitals of our group," said Borun Group Director Zhongping Meng. "Many thanks to ReCell for bringing benefit to more and more Chinese vitiligo patients." China has an estimated 12 million vitiligo sufferers, of which about 1.4 million1 are regarded as acute, and appropriate for ReCell ® treatment. Avita's approach works by delivering viable, pigment-producing cells harvested from a piece of the patient's own normally-pigmented skin and is administered by spraying the cells onto the affected area. During the conference series, entitled China, Australia, the Netherlands ReCell® Cell Regeneration Vitiligo Clinical Academic Achievements Transformation Workshop, Dr. Wolkerstorfer reviewed results from a randomized clinical trial done at his institute, which showed a ReCell®-treated group achieved 78% repigmentation, compared with 0% in the Control. ABOUT RECELL® AND RES™

ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin, yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin. ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, pending completion of the FDA approval trial, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com. 1. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. "Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families." Pigment Cell Research 16, no. 3 (2003): 208-214



FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]



USA

The Ruth Group

David Burke

Investor Relations

Kirsten Thomas

Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected]

/ [email protected]



Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

[email protected]





Read more...
Regenerative Medicine Approach Delivers Healing and Cost Savings for Chronic Wounds

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - May 1, 2016) - Avita Medical (ASX: AVH) (OTCQX: AVMXY)

Early intervention key for optimum treatment of chronic wound patients
ReGenerCell™ healing of diabetic foot ulcers described as 'remarkable'
Combined treatment has potential to considerably reduce woundcare costs

Early intervention with ReGenerCell™ can kick-start the closure of hard-to-heal ulcers, and save public health bodies significant money, according to leading UK vascular surgeons who are experienced users of the medical device, Avita Medical said today. The regenerative medicine company, specializing in the treatment of wounds and skin defects (ASX: AVH), (OTCQX: AVMXY), reported that presentations about using the device for diabetic foot ulcers (DFU) and venous leg ulcers (VLU) were made last week in London at the Charing Cross Symposium, one of the largest global gatherings for vascular surgeons. Faster healing and reduction in pain were both highlighted as benefits of deploying ReGenerCell™ by Mr. Paul Hayes, Cambridge Universities Hospitals Trust, UK, and Mr. Harvey Chant, Royal Cornwall Hospitals NHS Trust, UK. The ReGenerCell™ device allows medical professionals to use a small skin sample to quickly create a Regenerative Epithelial Suspension (RES™), which can then be applied to trigger wound healing. Mr. Chant, in Diabetic Vascular Disease and Wound Healing sessions, which focused on saving limbs, relayed to the audience how he had deployed ReGenerCell™ as part of a multi-disciplinary approach for diabetic foot treatment. In a recent pilot study of seven patients, treatment with the device healed five patients, which was encouraging as all other approaches had failed. "With the UK projected to have 4 million diabetics by 2025 any approach that could significantly reduce the burden of this debilitating condition for the patient and the health system must be explored," he said. "Frontline treatment has to be about the basics -- diabetic control, infection control and correct footwear," Mr. Chant said. "However, once patients have an ulcer, current treatment is lengthy and could end in amputation. By using ReGenerCell™ as part of the treatment toolbox at an earlier stage, the healing we have achieved has been remarkable, allowing most patients to get back to full function more quickly and improving their quality of life." Mr. Hayes, who is resident at Addenbrooke's Hospital, during the 'Innovations Showcase' gave the first public presentation of the recent pilot multi-centre randomised controlled trial of ReGenerCell™ in VLUs, a condition that imposes considerable costs on healthcare services, which are rising steadily because prevalence increases with age. In his presentation, Mr. Hayes explained that 52 patients (average age 69.7 years) with co-morbidities including well-controlled diabetes, peripheral arterial disease, arthritis and cardiovascular disease, participated in the trial, run at seven hospitals, comparing ReGenerCell™ and conventional VLU treatment, to conventional treatment alone. Mr. Hayes said the trial showed statistical significance in the primary endpoint of wound closure, with VLUs in the ReGenerCell™ group closing on average 9.1 cm2 compared to 1.2 cm2 in the control. Patients in the treated group also reported a significant decrease in pain two weeks after treatment and consistent improvements with all evaluated areas as wounds healed. Positive changes in re-epithelialisation were observed by weeks 1, 2, 4 and 6 with some cases achieving 100% closure by week 12, while slower wounds demonstrated a healing trajectory. A more marked healing rate was observed in larger ulcers, Mr. Hayes reported. "I think the burden of chronic wounds to the NHS is huge and under-recognised," Mr. Hayes said. "With ReGenerCell™ we have a one-off 30-minute procedure that shows it can kick-start healing. Any upfront cost for this therapy is more than exceeded by other savings. We have patients who have suffered VLUs for years, even decades, and any approach that breaks this cycle is worthy of exploration." Adam Kelliher, CEO of Avita Medical, said: "These presentations once again show that our novel approach to chronic woundcare, using a patient's regenerative healing capability, can alleviate patient suffering at an earlier stage, help them regain their quality of life and ultimately reduce costs to financially-stretched healthcare systems."  ABOUT CHARING CROSS SYMPOSIUM The Charing Cross Symposium first took place in 1978 at Charing Cross Hospital, Hammersmith, London, and is the longest running vascular and endovascular symposium in Europe and one of the largest in the world. This year's symposium focused on challenges in complete optimal vascular disease management, catering for all vascular specialists. For further information, visit: www.cxsymposium.com ABOUT AVITA MEDICAL LIMITED Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's regenerative product portfolio includes ReCell® for burns aimed at plastic reconstructive procedures, ReGenerCell™ for chronic wounds and ReNovaCell™ of restoration of pigmentation and cosmesis. ReCell®, ReGenerCell™ and ReNovaCell™ are patented, CE‐marked for Europe. ReCell® is TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. trial is well underway aimed at securing FDA approval. To learn more, visit www.avitamedical.com.


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269770

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone: 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone: 44 (0)20 7866 7860

[email protected]


USA

The Ruth Group

Lee Roth

Investor Relations

Kirsten Thomas

Public Relations

Phone: 1 (646) 536-7012 / 1 (508) 280-6592

[email protected]

/ [email protected]


Australia

Monsoon Communications

Rudi Michelson

Investor Relations / PR

Phone: 61 3 9620 3333

[email protected]





Read more...

Ratios

vs
industry
vs
history
PB Ratio 5.63
AVMXY's PB Ratio is ranked lower than
79% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. AVMXY: 5.63 )
Ranked among companies with meaningful PB Ratio only.
AVMXY' s PB Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.79 Max: 15
Current: 5.63
0.21
15
PS Ratio 45.00
AVMXY's PS Ratio is ranked lower than
93% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. AVMXY: 45.00 )
Ranked among companies with meaningful PS Ratio only.
AVMXY' s PS Ratio Range Over the Past 10 Years
Min: 1.43  Med: 9.29 Max: 70
Current: 45
1.43
70
EV-to-EBIT -4.79
AVMXY's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. AVMXY: -4.79 )
Ranked among companies with meaningful EV-to-EBIT only.
AVMXY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.8  Med: -2.2 Max: 1.2
Current: -4.79
-8.8
1.2
EV-to-EBITDA -4.79
AVMXY's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. AVMXY: -4.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVMXY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.3  Med: -2.5 Max: 2
Current: -4.79
-14.3
2
Current Ratio 11.89
AVMXY's Current Ratio is ranked higher than
97% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. AVMXY: 11.89 )
Ranked among companies with meaningful Current Ratio only.
AVMXY' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 5.62 Max: 195.06
Current: 11.89
0.02
195.06
Quick Ratio 10.79
AVMXY's Quick Ratio is ranked higher than
96% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. AVMXY: 10.79 )
Ranked among companies with meaningful Quick Ratio only.
AVMXY' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 5.07 Max: 195.06
Current: 10.79
0.02
195.06
Days Inventory 1.00
AVMXY's Days Inventory is ranked higher than
99% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. AVMXY: 1.00 )
Ranked among companies with meaningful Days Inventory only.
AVMXY' s Days Inventory Range Over the Past 10 Years
Min: 1  Med: 358.08 Max: 892.52
Current: 1
1
892.52
Days Sales Outstanding 728.08
AVMXY's Days Sales Outstanding is ranked lower than
100% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. AVMXY: 728.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVMXY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 98.69  Med: 179.48 Max: 736.19
Current: 728.08
98.69
736.19
Days Payable 737.80
AVMXY's Days Payable is ranked higher than
99% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. AVMXY: 737.80 )
Ranked among companies with meaningful Days Payable only.
AVMXY' s Days Payable Range Over the Past 10 Years
Min: 112.97  Med: 328.22 Max: 1400.07
Current: 737.8
112.97
1400.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.40
AVMXY's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. AVMXY: -17.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVMXY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -93.8  Med: -36.6 Max: 0
Current: -17.4
-93.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.00
AVMXY's Price-to-Net-Cash is ranked higher than
65% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. AVMXY: 9.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AVMXY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.93  Med: 3.98 Max: 25.2
Current: 9
0.93
25.2
Price-to-Net-Current-Asset-Value 4.50
AVMXY's Price-to-Net-Current-Asset-Value is ranked higher than
61% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. AVMXY: 4.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVMXY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.67  Med: 3.91 Max: 19.38
Current: 4.5
0.67
19.38
Price-to-Tangible-Book 5.63
AVMXY's Price-to-Tangible-Book is ranked lower than
67% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. AVMXY: 5.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVMXY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.57  Med: 3.57 Max: 18.33
Current: 5.63
0.57
18.33
Earnings Yield (Greenblatt) % -20.88
AVMXY's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. AVMXY: -20.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVMXY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -20.88  Med: 351.7 Max: 11345.6
Current: -20.88
-20.88
11345.6

More Statistics

Revenue (TTM) (Mil) $0.70
EPS (TTM) $ -0.21
Beta-0.12
Short Percentage of Float0.00%
52-Week Range $1.33 - 2.29
Shares Outstanding (Mil)33.65
» More Articles for AVMXY

Headlines

Articles On GuruFocus.com
Avita Medical's ReCell(R) devices now treating burns in South Africa and Benelux Oct 19 2016 
U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell(R) in Life-Threaten Oct 18 2016 
Avita Medical to Present at the 2016 Dawson James Securities Growth Stock Conference in Florida Oct 13 2016 
FDA Approves Continued Access to ReCell(R) in US Burns Trial Oct 04 2016 
Avita Medical Signs Exclusive Distributor Deal in Iran Sep 29 2016 
Avita Medical to Hold ReCell(R) Symposium at Leading European Burns Association Course Sep 22 2016 
Avita Medical Appoints a Leading Health Economics Group Jun 28 2016 
Regenerative Medicine Publishes Key Findings From Avita Medical's 2016 Skin Regeneration Symposium Jun 27 2016 
Avita Medical Awarded US$7.96m in BARDA Extension Deal Jun 26 2016 
Avita Medical to Present at Global Chinese Financial Forum Jun 22 2016 

More From Other Websites
Avita Medical CEO Shareholder Letter and Quarterly Report Apr 27 2017
U.S. FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell® in... Apr 06 2017
Avita Medical to Present at Needham Healthcare Conference Mar 23 2017
Avita Announces Receipt of $975K R&D Tax Incentive Mar 15 2017
Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial Mar 06 2017
Avita Medical Named to 2017 OTCQX Best 50 Feb 28 2017
Avita Medical to Participate in the 3rd Annual Biotech and Money / Medtech and Money London 2017... Jan 24 2017
Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits... Nov 28 2016
Innovative Regenerative Approach to Healing Diabetic Foot Ulcers Now Being Trialed at Two Additional... Nov 08 2016
Avita Medical's ReCell(R) devices now treating burns in South Africa and Benelux Oct 19 2016
Avita Medical to Present at the 2016 Dawson James Securities Growth Stock Conference in Florida Oct 13 2016
Avita Medical Signs Exclusive Distributor Deal in Iran Sep 28 2016
Avita Medical to Hold ReCell(R) Symposium at Leading European Burns Association Course Sep 22 2016
Avita Medical's Regenerative Skin Technology Significantly Reduces Burn Scars and Healing Time Sep 01 2016
Avita Medical Announces Financial Results for Fourth Quarter Fiscal 2016 Jul 28 2016
Avita Medical Announces Rights Issue Raises $9 Million Jul 10 2016
Avita Medical Appoints a Leading Health Economics Group Jun 28 2016
Regenerative Medicine Publishes Key Findings From Avita Medical's 2016 Skin Regeneration Symposium Jun 27 2016
Avita Medical Awarded US$7.96m in BARDA Extension Deal Jun 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)